28.46
price up icon0.21%   0.06
after-market 시간 외 거래: 28.46
loading
전일 마감가:
$28.40
열려 있는:
$28.25
하루 거래량:
1.16M
Relative Volume:
0.75
시가총액:
$4.05B
수익:
$10.12M
순이익/손실:
$-280.49M
주가수익비율:
-9.8478
EPS:
-2.89
순현금흐름:
$-188.51M
1주 성능:
-4.72%
1개월 성능:
-8.13%
6개월 성능:
-2.13%
1년 성능:
-31.06%
1일 변동 폭
Value
$27.70
$29.46
1주일 범위
Value
$27.70
$30.52
52주 변동 폭
Value
$21.51
$56.00

어비디티 바이오사이언스 Stock (RNA) Company Profile

Name
명칭
Avidity Biosciences Inc
Name
전화
858-401-7900
Name
주소
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
직원
391
Name
트위터
Name
다음 수익 날짜
2024-12-07
Name
최신 SEC 제출 서류
Name
RNA's Discussions on Twitter

RNA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RNA
Avidity Biosciences Inc
28.46 4.05B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-11 개시 Raymond James Strong Buy
2025-03-13 개시 Citigroup Buy
2025-03-12 개시 BMO Capital Markets Outperform
2025-03-07 개시 Scotiabank Sector Outperform
2024-12-20 개시 H.C. Wainwright Buy
2024-11-26 개시 RBC Capital Mkts Outperform
2024-09-24 개시 Goldman Buy
2024-08-28 개시 Barclays Overweight
2024-05-03 개시 BofA Securities Buy
2024-03-14 개시 Cantor Fitzgerald Overweight
2023-05-22 업그레이드 Evercore ISI In-line → Outperform
2023-03-31 다운그레이드 Evercore ISI Outperform → In-line
2022-07-20 개시 Chardan Capital Markets Buy
2022-07-12 개시 Raymond James Strong Buy
2021-09-07 개시 Evercore ISI Outperform
2021-06-17 개시 Needham Buy
2021-04-26 재개 Credit Suisse Outperform
2020-07-07 개시 Cowen Outperform
2020-07-07 개시 Credit Suisse Outperform
2020-07-07 개시 SVB Leerink Outperform
2020-07-07 개시 Wells Fargo Overweight
모두보기

어비디티 바이오사이언스 주식(RNA)의 최신 뉴스

pulisher
Jun 18, 2025

Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

(RNA) Proactive Strategies - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter

Jun 15, 2025
pulisher
Jun 14, 2025

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia

Jun 14, 2025
pulisher
Jun 14, 2025

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa

Jun 14, 2025
pulisher
Jun 13, 2025

Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Avidity Biosciences (RNA) Receives Strong Buy Rating from Raymond James | RNA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress – Company AnnouncementFT.com - Financial Times

Jun 11, 2025
pulisher
Jun 11, 2025

Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation - MSN

Jun 11, 2025
pulisher
Jun 10, 2025

Avidity Biosciences holds annual stockholders meeting By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Avidity Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Avidity Biosciences holds annual stockholders meeting - Investing.com

Jun 10, 2025
pulisher
Jun 10, 2025

Avidity Biosciences price target raised to $75 from $65 at Chardan - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

JP Morgan Raises Price Target for Avidity Biosciences (RNA) to $59 | RNA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts - Nasdaq

Jun 10, 2025
pulisher
Jun 10, 2025

Avidity Biosciences (RNA) Sees Price Target Increase Amid Promis - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Avidity Biosciences (RNA) Gains Boost with New Price Target and Accelerated Approval Path | RNA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Barclays Raises Target Price for Avidity Biosciences (RNA) | RNA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Avidity Biosciences (RNA) Price Target Raised Amid Positive Deve - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

RNA: Avidity Biosciences Maintains Buy Rating with Price Target Increase | RNA Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity reports promising FSHD therapy trial results By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD - StreetInsider

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences (RNA) Seeks Accelerated Approval for Key Drug | RNA Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences stock falls following positive trial data By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences stock falls following positive trial data - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

BofA lifts Avidity Biosciences stock target to $54 By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial - Yahoo

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences (RNA) Price Target Raised Amid Positive Developments | RNA Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences (RNA) Receives Enhanced Price Target Followi - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Avidity Biosciences, Inc.Shareholder/Analyst Call - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences (RNA) Receives Enhanced Price Target Following Trial Results | RNA Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences Shares Face Turbulence Amid Mixed Signals - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences (RNA) Reports Promising Results from FSHD Treatment Study | RNA Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences (RNA) Advances Del-brax Approval Pathway for FSHD Treatment | RNA Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity reports promising FSHD therapy trial results - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Breakthrough FSHD Drug Trial Success: First-Ever Treatment Shows Multiple Improvements in Muscle Disease - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD – Company Announcement - Financial Times

Jun 09, 2025
pulisher
Jun 06, 2025

Stocks Flashing Renewed Technical Strength: Avidity Biosciences - Investor's Business Daily

Jun 06, 2025
pulisher
Jun 04, 2025

(RNA) Investment Analysis - news.stocktradersdaily.com

Jun 04, 2025
pulisher
May 28, 2025

Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces hurdles - Investing.com Nigeria

May 28, 2025
pulisher
May 27, 2025

Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com

May 27, 2025

어비디티 바이오사이언스 (RNA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
자본화:     |  볼륨(24시간):